Pacgen Biopharmaceuticals using innovative technology in study of
anti-infective drug
RESEARCH TRIANGLE PARK, N.C., March 5 /PRNewswire/ -- Quintiles
Transnational Corp. today announced it has achieved another major milestone
in the management of clinical trial data -- 300 clinical trials using
Electronic Data Capture (EDC).
The milestone EDC trial is a Phase II study being conducted for Pacgen
Biopharmaceuticals Corporation of Vancouver, British Columbia. Pacgen is
studying an anti-infective drug for the treatment of oral candidiasis.
Quintiles began using EDC in 1999 and has seen acceptance of the technology
accelerate since then, with more than 94 EDC trials put into production in
2007.
"At Quintiles, EDC is quickly surpassing paper in the collection of
clinical trial data as customers are placing increased value on our ability
to give them expert guidance in the appropriate use of this technology, as
well as the potential for savings in time and cost," said Paula Brown
Stafford, Executive Vice President, Global Data Management and
Biostatistics, and a member of the CDISC Board of Directors. "We have been
able to demonstrate for the pharmaceutical and biotech industries that EDC,
when used properly, can make much better use of available resources.
"With Pacgen, we're working with an emerging biopharmaceutical company
that is conducting important research in infectious diseases," she added.
"Quintiles looks forward to continuing to help Pacgen further develop its
pipeline."
About Pacgen
Pacgen is a life sciences company focused on the development of
therapeutics for the treatment of infectious and inflammatory diseases. The
company's lead product, PAC-113, is an anti-fungal in a Phase II clinical
program. Pacgen also has candidates in an early stage research program. The
most advanced of these candidates is a novel peptide therapeutic, PAC-G31P,
which is currently being investigated in preclinical studies for its
potential to treat inflammatory diseases characterized by non-beneficial
neutrophil recruitment and activation.
About Quintiles
Quintiles Transnational Corp. is powering the next generation of
healthcare by providing a broad range of professional services in drug
development, financial partnering and commercialization for the
pharmaceutical, biotechnology and healthcare industries. With more than
19,000 employees and offices in more than 50 countries, it is focused on
providing customer-centric solutions that are the gold standard of the
industry. For more information, please visit the company's Web site at
http://www.quintiles.com .
SOURCE Quintiles Transnational Corp.
 back to top
Related links:
http://www.quintiles.com
CONTACT:
Media Relations, Dick Jones, +1-919-998-2091,
media.info@quintiles.com, or Investor Relations, Greg Connors,
+1-919-998-2000, invest@quintiles.com, both of Quintiles
Transnational Corp.
|
